|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,614,520: Olanzapine Polymorphs
U.S. Patent 5,614,520, granted on March 23, 1997, to Eli Lilly and Company, claims novel crystalline forms of olanzapine, aripiprazole, and their salts. The patent specifically addresses polymorphs of olanzapine, particularly crystalline forms designated as Form I and Form II, and their salts. These forms exhibit distinct X-ray diffraction patterns and thermal properties, impacting the drug's stability, solubility, and bioavailability. The patent's claims are directed at the crystalline forms themselves, compositions containing them, and methods of preparing these forms.
What is the Core Invention Claimed in U.S. Patent 5,614,520?
The primary invention protected by U.S. Patent 5,614,520 is the identification and characterization of specific crystalline polymorphs of olanzapine. Polymorphs are different crystal structures of the same chemical compound. For olanzapine, a second-generation antipsychotic used to treat schizophrenia and bipolar disorder, the crystalline form can significantly influence its pharmaceutical properties. The patent claims:
- Olanzapine crystalline forms: Specifically, crystalline olanzapine, characterized by a unique X-ray powder diffraction pattern, and crystalline olanzapine having a distinct thermal analysis profile. These are often referred to as Form I and Form II.
- Salts of olanzapine crystalline forms: Crystalline forms of olanzapine salts, exhibiting characteristic X-ray diffraction patterns.
- Pharmaceutical compositions: These compositions contain at least one of the claimed crystalline forms of olanzapine or its salts.
- Methods of preparation: Processes for preparing the claimed crystalline forms.
The patent's specification details methods for obtaining these specific crystalline forms, often involving controlled crystallization processes. The importance lies in the ability to consistently produce a desired polymorph with optimized properties for drug formulation and efficacy.
What are the Key Polymorphs and Their Characteristics Covered by the Patent?
U.S. Patent 5,614,520 describes and claims at least two distinct crystalline forms of olanzapine, referred to as Form I and Form II. These forms are distinguished by their unique physical properties, particularly their X-ray powder diffraction (XRPD) patterns and thermal behavior.
- Form I: Characterized by an XRPD pattern showing specific peaks at diffraction angles (2θ) such as approximately 6.6, 11.5, 14.6, 18.2, 22.9, and 27.3 degrees. Its differential scanning calorimetry (DSC) profile shows a melting point of approximately 152-154°C.
- Form II: Characterized by an XRPD pattern with specific peaks at diffraction angles (2θ) such as approximately 8.5, 16.9, 18.5, 20.1, 22.1, and 24.8 degrees. Its DSC profile shows a melting point of approximately 162-164°C.
The patent also covers crystalline forms of salts of olanzapine, providing XRPD data for these as well. The ability to control and identify these specific crystalline structures is critical for ensuring consistent drug product quality, stability, and predictable therapeutic outcomes.
What is the Scope of the Claims in U.S. Patent 5,614,520?
The claims of U.S. Patent 5,614,520 are directed towards the novel crystalline forms of olanzapine and its salts, rather than the olanzapine molecule itself, which was known prior to this patent. The scope is defined by the specific physical characteristics of these crystalline forms.
Key claim categories include:
- Claim 1: This is an independent claim defining crystalline olanzapine characterized by an X-ray powder diffraction pattern. The claim recites specific peak positions in degrees 2-theta.
- Dependent Claims: Numerous dependent claims further define the crystalline forms by adding further specific XRPD peaks or by referring to thermal characteristics (e.g., DSC profiles).
- Salt Claims: Claims specifically cover crystalline forms of olanzapine salts, again defined by their XRPD patterns.
- Composition Claims: Claims protect pharmaceutical compositions that incorporate these specific crystalline forms. This means any drug product containing a defined crystalline form of olanzapine, as described in the patent, would fall under the scope.
- Method Claims: Claims may cover specific methods for preparing these crystalline forms.
The scope is significant because it protects specific physical manifestations of the olanzapine molecule that exhibit advantageous properties. It targets manufacturers or formulators using these particular crystalline structures in their drug products.
What is the Status of U.S. Patent 5,614,520 and its Prosecution History?
U.S. Patent 5,614,520 was granted on March 23, 1997. The patent has since expired.
- Issue Date: March 23, 1997
- Original Expiration Date: March 23, 2014 (based on a 17-year term from issuance for patents filed before June 8, 1995).
- Term Extensions: It is possible that patent term extensions (PTE) were sought and granted for this patent, which would have extended the exclusivity period to compensate for regulatory review delays. However, based on the original term, the patent is no longer in force.
Prosecution History Highlights (General Trends for such patents):
While specific detailed prosecution history requires access to USPTO Public PAIR, typical prosecution for a patent claiming novel crystalline forms involves:
- Prior Art Challenges: Examiners often cite existing patents or scientific literature describing olanzapine and its known crystalline forms or methods of preparation.
- Obviousness Arguments: Applicants must demonstrate that the claimed crystalline forms are not obvious variations of known forms or methods. This often involves presenting evidence of distinct physical properties (XRPD, DSC, TGA) and potentially functional differences in stability, solubility, or processability.
- Claim Amendments: Claims are often refined to specifically define the novel crystalline forms using precise analytical data, such as XRPD peak positions and thermal events, to distinguish them from prior art.
- Interference/Derivation Proceedings: In some cases, disputes over inventorship or derivation of the invention may arise.
The patent's expiration means that the claims covering the specific crystalline forms of olanzapine and their preparation are now in the public domain.
What is the Patent Landscape Surrounding U.S. Patent 5,614,520?
The patent landscape for olanzapine is complex, with numerous patents covering the active pharmaceutical ingredient (API), various salt forms, crystalline polymorphs, methods of synthesis, and pharmaceutical formulations. U.S. Patent 5,614,520 is one piece of this landscape, focusing specifically on distinct crystalline forms.
Key aspects of the olanzapine patent landscape include:
- Composition of Matter Patents: The original patent covering the olanzapine molecule itself (likely expired much earlier) would have been the foundational patent.
- Polymorph Patents: U.S. Patent 5,614,520 is an example of a patent claiming specific crystalline forms. Other patents in this space may claim different polymorphs, solvates, or hydrates of olanzapine, or novel salt forms with improved properties.
- Process Patents: Patents covering novel or improved synthetic routes to olanzapine API.
- Formulation Patents: Patents claiming specific dosage forms (e.g., tablets, orally disintegrating tablets, long-acting injectables) or excipient combinations that improve drug delivery, stability, or patient compliance.
- Method of Treatment Patents: Patents claiming the use of olanzapine for specific therapeutic indications or patient populations.
Impact of U.S. Patent 5,614,520's Expiration:
The expiration of U.S. Patent 5,614,520, and potentially any associated PTEs, has significant implications:
- Generic Entry: Once the patent protecting specific crystalline forms expires, generic manufacturers can more readily produce and market olanzapine products utilizing these forms. This typically leads to increased competition and lower drug prices.
- Formulation Freedom: Generic companies are not necessarily bound by the innovator's specific formulation patents, but they must respect any patents covering the crystalline forms themselves as long as those patents are in force. With 5,614,520 expired, the freedom to use these specific polymorphs increases for generics.
- Ongoing Litigation: Even after patent expiration, there can be legacy litigation concerning inventorship, validity challenges, or infringement that occurred during the patent's active life. However, for expired patents, the primary focus shifts to new market entrants.
Key Competitors and Innovators in the Olanzapine Space:
Eli Lilly and Company, the assignee of U.S. Patent 5,614,520, is the innovator company. Major generic pharmaceutical companies, such as Teva Pharmaceuticals, Sandoz, Mylan (now Viatris), and Dr. Reddy's Laboratories, are active in the olanzapine market. The landscape is characterized by a well-established generic presence for olanzapine.
What are the Commercial Implications of U.S. Patent 5,614,520 and its Expiration?
The commercial implications of U.S. Patent 5,614,520 primarily relate to its role in protecting innovator exclusivity and its subsequent expiration enabling generic competition.
- Innovator Market Protection: During its term, the patent granted Eli Lilly and Company market exclusivity for olanzapine products that incorporated the specific crystalline forms claimed. This exclusivity allowed Lilly to recoup R&D investment and establish a strong market position for its branded olanzapine product, Zyprexa.
- Barriers to Entry for Generics: The patent acted as a barrier to entry for generic manufacturers who wished to use those particular crystalline forms. Generic companies had to either develop alternative crystalline forms (if patentable and commercially viable) or wait for the patent to expire.
- Increased Competition Post-Expiration: The expiration of U.S. Patent 5,614,520, along with other relevant patents covering olanzapine, has been a critical factor in the widespread availability of generic olanzapine. This has led to:
- Price Reduction: Generic competition drives down the cost of olanzapine, making treatment more affordable.
- Market Share Shift: The market share for branded Zyprexa has significantly declined as generic alternatives have captured a substantial portion of the market.
- Supply Chain Diversification: Multiple manufacturers now supply olanzapine API and finished dosage forms, creating a more robust and diversified supply chain.
- Ongoing Strategy for Innovators: For innovator companies, the strategy after such foundational patents expire often involves focusing on newer formulations (e.g., long-acting injectables, novel delivery systems) or next-generation molecules to maintain market leadership and differentiate their offerings.
The patent's specific focus on crystalline forms underscores the pharmaceutical industry's practice of seeking patent protection for not just the chemical entity but also its different physical states, which can significantly impact drug performance and manufacturing.
What are the Regulatory Considerations Related to U.S. Patent 5,614,520?
The regulatory considerations surrounding U.S. Patent 5,614,520 are primarily linked to patent listing in the FDA's Orange Book and the Hatch-Waxman Act's framework for generic drug approval.
- Orange Book Listing: Patents relevant to an approved drug product, including those covering the active ingredient, specific polymorphs, or formulations, are listed in the U.S. Food and Drug Administration's (FDA) "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly known as the Orange Book. U.S. Patent 5,614,520 would have been listed for Eli Lilly's olanzapine products if it was deemed relevant to the approved composition or manufacturing process.
- Patent Certification by Generic Applicants: Under the Hatch-Waxman Act, generic drug applicants must certify their position relative to any patents listed in the Orange Book for the reference listed drug (RLD). This involves:
- Paragraph I Certification: Stating that no patent information has been filed.
- Paragraph II Certification: Stating that the patent has expired.
- Paragraph III Certification: Stating that the applicant will wait for the patent to expire before approving their ANDA (Abbreviated New Drug Application).
- Paragraph IV Certification: Stating that the patent is invalid, unenforceable, or will not be infringed by the generic product. This often triggers a 30-month stay on ANDA approval, during which patent litigation may occur.
- Patent Term Extension (PTE): If Eli Lilly sought and was granted a PTE for U.S. Patent 5,614,520, this would have extended the effective market exclusivity period beyond the original expiration date, directly impacting the timeline for generic entry. Regulatory authorities grant PTEs to compensate for patent term lost during the FDA regulatory review period.
- ANDA Approval Process: Generic manufacturers seeking approval for an olanzapine product must demonstrate bioequivalence to the RLD and must address all relevant listed patents. The approval of an ANDA is contingent upon the patent landscape. If a Paragraph IV certification was filed and the patent litigation was resolved in favor of the generic applicant, or if the patent expired, the ANDA could be approved.
The status of U.S. Patent 5,614,520 as expired means that generic applicants are generally free to utilize the claimed crystalline forms without infringing this specific patent, provided no other valid patents cover their intended product or process.
Key Takeaways
- U.S. Patent 5,614,520 claimed novel crystalline polymorphs of olanzapine, specifically Form I and Form II, and their salts, along with compositions and methods of preparation.
- These polymorphs are differentiated by their distinct X-ray powder diffraction (XRPD) patterns and thermal properties, crucial for drug stability and performance.
- The patent was granted to Eli Lilly and Company and expired on March 23, 2014, without considering any potential patent term extensions.
- The expiration of this patent, along with others in the olanzapine space, has facilitated generic market entry, leading to increased competition and reduced drug pricing.
- Regulatory frameworks like the Hatch-Waxman Act and FDA's Orange Book dictate how generic drug approvals interact with and are influenced by patent exclusivity periods.
FAQs
-
Can generic manufacturers currently use the crystalline forms claimed in U.S. Patent 5,614,520?
Yes, as U.S. Patent 5,614,520 has expired, generic manufacturers are generally free to utilize the crystalline forms it claimed, provided no other valid and in-force patents cover their specific product or manufacturing process.
-
What is the significance of claiming specific crystalline forms (polymorphs) of a drug like olanzapine?
Claiming specific polymorphs allows patent holders to protect distinct physical forms of an active pharmaceutical ingredient that may exhibit superior properties such as enhanced stability, improved solubility, better bioavailability, or more efficient manufacturing processes compared to other known forms.
-
How does the expiration of U.S. Patent 5,614,520 affect the price of olanzapine?
The expiration of patents, including those covering specific crystalline forms, removes barriers to generic competition. Increased competition typically leads to a significant reduction in the price of the drug as multiple manufacturers enter the market.
-
Does the expiration of U.S. Patent 5,614,520 mean all olanzapine patents have expired?
No, the expiration of a single patent does not signify the end of all patent protection for a drug. Olanzapine may still be covered by other patents, such as those related to specific salt forms, improved synthesis methods, or novel pharmaceutical formulations (e.g., orally disintegrating tablets, long-acting injections).
-
Where can I find the detailed X-ray powder diffraction (XRPD) data and differential scanning calorimetry (DSC) profiles mentioned for the crystalline forms in U.S. Patent 5,614,520?
The specific XRPD data, including peak positions in degrees 2-theta, and DSC profiles (e.g., melting points) are detailed within the specification and figures of U.S. Patent 5,614,520 itself. This patent document is publicly accessible through the United States Patent and Trademark Office (USPTO) website or other patent databases.
Citations
[1] Eli Lilly and Company. (1997). U.S. Patent 5,614,520: Crystalline Forms of Aripiprazole and Olanzapine and Salts Thereof. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
